Psilocybin and MDMA therapy for PTSD in veterans
Treatments studied
Part of Mental health clinical trials.
This study tests whether a combination of two investigational drugs, psilocybin and MDMA, can help veterans with post-traumatic stress disorder (PTSD). You would receive the drugs in a controlled setting and be monitored closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a military veteran aged 21 or older.
- You have been diagnosed with PTSD for at least 6 months and have moderate to severe symptoms (CAPS-5 score of 28 or higher).
- You are not at high risk for suicide and have a supportive contact person who can be reached if needed.
- You have limited prior use of psychedelic drugs (never more than a 'microdose') and are willing to stop certain medications and supplements before sessions.
- You have no serious mental health conditions like schizophrenia or bipolar disorder, and no recent severe substance use disorder (except cannabis).
- You are medically stable, with no uncontrolled heart problems or other conditions that would make MDMA or psilocybin unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different doses of MDMA (a drug sometimes called 'ecstasy') combined with therapy to see which dose works best for treating PTSD in veterans. The goal is to find a safer, more effective dose to help reduce PTSD symptoms.
This study tests whether MDMA (a medication) combined with therapy can help veterans with post-traumatic stress disorder (PTSD). MDMA may help people process difficult memories and emotions more effectively during therapy sessions.
This study tests whether a guided psilocybin session can help veterans heal from trauma-related PTSD. If you're a veteran with PTSD, you may be able to join.
This study tests whether a drug called psilocybin (the active ingredient in 'magic mushrooms') combined with therapy can help treat PTSD in military personnel and veterans. You'll receive the drug during a supervised session, along with talk therapy, to see if it reduces PTSD symptoms.
This Phase 2 trial tests whether therapy assisted by MDMA can reduce symptoms of moderate to severe post-traumatic stress disorder (PTSD) in eligible veterans. It includes supervised therapy sessions and extra study visits with video recording to track changes over time.
This study tests whether MDMA (a drug that can help people feel safe and open during therapy) combined with talk therapy can reduce PTSD symptoms in active-duty service members, National Guard, and Reserve members. If you are struggling with PTSD that has lasted at least 6 months, this trial may offer a new treatment option.
Hear when a new Posttraumatic Stress Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.